Inventor · disambiguated record
Francois Gaudet
Also filed as: GAUDET FRANCOIS · GAUDET FRANÇOIS
11 granted patents·11 pending applications·86 citations·filing 2015–2024
89Inventor score
Top patents by PatentIndex Score
22 records- 0195US10072088B2Anti-BCMA antibodies and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Sep 11, 2018·30 cites·16 claims
- 0292US10562968B2Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Feb 18, 2020·18 cites·19 claims
- 0392US9850310B2CD123 binding agents and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Dec 26, 2017·23 cites·20 claims
- 0491US12077592B2GPRC5D chimeric antigen receptors and cells expressing the sameJANSSEN BIOTECH INC·Filed 2020·Granted Sep 3, 2024·3 cites·36 claims
- 0589US11884722B2Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereofJANSSEN BIOTECH INC·Filed 2023·Granted Jan 30, 2024·1 cites·25 claims
- 0688US11603405B2Anti-CD3 antibodies and uses thereofJANSSEN BIOTECH INC·Filed 2019·Granted Mar 14, 2023·4 cites·45 claims
- 0786US10844122B2Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereofJANSSEN BIOTECH INC·Filed 2016·Granted Nov 24, 2020·4 cites·8 claims
- 0881US11685777B2Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Jun 27, 2023·1 cites·9 claims
- 0978US2024343796A1Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereofJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1078US2024262921A1Gprc5d chimeric antigen receptors and cells expressing the sameJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1177US11466082B2Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereofJANSSEN BIOTECH INC·Filed 2019·Granted Oct 11, 2022·2 cites·21 claims
- 1275US2024301083A1Methods of treating cancers and enhancing efficacy of t cell redirecting therapeuticsJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1372US2024101697A1Methods of treating cancers and enhancing efficacy of t cell redirecting therapeuticsJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1468US2023322924A1Anti-cd3 antibodies and uses thereofJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1566US12065500B2Methods of treating cancers and enhancing efficacy of T cell redirecting therapeuticsJANSSEN BIOTECH INC·Filed 2019·Granted Aug 20, 2024·0 cites·28 claims
- 1666US12012461B2Methods of treating cancers and enhancing efficacy of T cell redirecting therapeuticsJANSSEN BIOTECH INC·Filed 2019·Granted Jun 18, 2024·0 cites·18 claims
- 1766US2024327514A1Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitorJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1855US2021363252A1Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitorJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 1952US2024228618A1Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeuticJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2048US2019270826A1Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Application pending·0 cites
- 2141US2017121420A1Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2016·Application pending·0 cites
- 2237US2017210799A1Anti-ror1, antibodies, ror1 x cd3 bispecific antibodies, and methods of using the sameJANSSEN BIOTECH INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Francois Gaudet files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →